Systemic sclerosis & Raynaud's
Prognostic significance of pericardial effusion in systemic sclerosis-associated pulmonary hypertension: analysis from the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS) Registry
Authors' conclusion
Persistent pericardial effusion, but not ever having had pericardial effusion or intermittent pericardial effusion, was independently associated with poorer survival.
Study context
- Population
- Patients with newly diagnosed SSc-PH (right heart catheterization), PHAROS registry, 2005 to 2016245 with ≥2 echocardiograms
- Participants
- 335 patients
- Exposure
- Pericardial effusion status in SSc-PH
- Outcome
- Survival
Methodological detailsmulticentre registry, Kaplan-Meier survival analyses, multivariable Cox proportional hazards regression
- Multicentre registry
- Kaplan-Meier survival analyses
- Multivariable Cox proportional hazards regression
Main finding
As reported in the abstract
Death (poorer survival) by pericardial effusion status
AHR for death (95% CI)P value
Persistent PEindependent predictor; multivariable-adjusted
2.34(1.20–4.64)
P = 0.002Intermittent PEnot a predictor; multivariable-adjusted
0.89(0.52–1.56)
P = 0.68Observational data: associations, not effects.
Further findings
| Outcome | P value |
|---|---|
| Survival, ever vs never pericardial effusionNot predictive of survival | log-rank test P = 0.49 |
Change in pericardial effusion status (patients with ≥2 echocardiograms) · average of 4.3 years of follow up
- Had a change in pericardial effusion status
- 44%
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Prognostic significance of pericardial effusion in systemic sclerosis-associated pulmonary hypertension: analysis from the PHAROS Registry. Rheumatology (Oxford). Published 21 July 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →